Lack of Supplier Qualification leads to Recall
Recommendation

14/15 October 2026
Vienna, Austria
Quality Oversight of Pharmaceutical Contract Manufacturing Organisations
The company Hospira Deutschland GmbH had to recall vials of their antibiotic drug Meropenem. The main reason for this was that a supplier of an important raw material was not qualified. As a result, this manufacturer was not listed in the respective authorisation and the batches affected did not correspond with the authorisation documents. According to a press release issued by Hospira GmbH (German text), the medical evaluation stated that "the risk of adverse events occurring as a result of this are to be considered low. There is currently no indication that patient safety was affected by the quality or efficacy."
Nevertheless, this example shows the negative and unpleasant consequences for companies and patients if suppliers are not or are inadequately qualified. A change notification for the supplier to be included in the authorisation documentation is currently in progress.
Related GMP News
12.10.2026EU Pharma Package: Council Adopts New Rules
12.10.2026ICH Publishes New Training Material for Quality Guidelines
12.10.2026WHO issues Draft Guidance on Quality Risk Management
26.08.2026GMP and "Planned Deviations" - a Contradiction?
19.08.2026Why Root Cause Analysis is the Key to efficient CAPA
19.08.2026EMA updates Guideline on implementing the Shortage Prevention Plan


